# Cybin Inc. (HELP) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.22, market value $893 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cybin Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.3×**. The shares trade at 5.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -11.5%** (5-yr avg -58.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -63.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -26.9%**. Each dollar of assets produces -26.9% of profit.

## Growth
- **EPS growth (1 yr): 24.0%**. Earnings per share rose 24.0%.

## Financial health
- **Current ratio: 9.52** (quick 9.52). Current assets cover the next year's liabilities 9.52 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Cybin Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 104.3%** (YTD 49.4%, 3-mo 194.5%). The shares are up 104.3% over twelve months including dividends.
- **From 52-week high: -14.8%** (225.0% above the low). Trading 15% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 2.16** (volatility 84%). Beta of 2.16 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HELP · Page: https://foliofundamentals.com/stocks/help

Not investment advice.